Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Short Interest Update

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 56,865 shares, a growth of 91.6% from the August 15th total of 29,679 shares. Based on an average daily trading volume, of 4,765,370 shares, the short-interest ratio is currently 0.0 days. Currently, 10.1% of the company’s shares are sold short.

Institutional Investors Weigh In On Jupiter Neurosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Allen Capital Group LLC acquired a new position in Jupiter Neurosciences during the 4th quarter worth approximately $31,000. Yorkville Advisors Global LP acquired a new stake in shares of Jupiter Neurosciences in the fourth quarter valued at approximately $135,000. Finally, Vestor Capital LLC grew its position in Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after purchasing an additional 970,314 shares in the last quarter.

Analyst Ratings Changes

Several brokerages recently commented on JUNS. Wall Street Zen raised Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research note on Sunday, August 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Jupiter Neurosciences presently has a consensus rating of “Sell”.

Jupiter Neurosciences Trading Down 2.7%

Shares of JUNS stock traded down $0.08 during trading hours on Wednesday, hitting $2.93. 22,036 shares of the company were exchanged, compared to its average volume of 380,711. Jupiter Neurosciences has a 52 week low of $2.88 and a 52 week high of $137.96. The business has a 50 day moving average of $7.09 and a two-hundred day moving average of $18.76. The company has a market capitalization of $2.67 million, a PE ratio of -0.15 and a beta of 1.81.

Jupiter Neurosciences (NASDAQ:JUNS) last announced its earnings results on Friday, August 14th. The company reported ($5.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.75) by ($1.31). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.40 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.